FDA grants expanded access for Tekmira's TKM-Ebola

Tekmira Pharmaceuticals Corp. (TSX:TKM; NASDAQ:TKMR) jumped $3.45 (17%) to $23.61 in New York and C$3.39 (15%) to C$26.01 in Toronto on Monday after FDA granted expanded access use of TKM-Ebola in patients with confirmed or suspected Ebola infections. Tekmira also said Health Canada established a similar framework.

Last month, FDA converted a full hold on a Phase I trial of TKM-Ebola to a partial hold, which allowed for the potential use of the product in Ebola-infected individuals (see BioCentury Extra, Aug. 8). ...